Targeting interferon-alpha to dendritic cells enhances a CD8+ T cell response to a human CD40-targeted cancer vaccine

Publication date: 16 August 2017
Source:Vaccine, Volume 35, Issue 35, Part B
Author(s): John P. Graham, Pierre Authie, A. Karolina Palucka, Gerard Zurawski
Targeting antigens to antigen presenting cells (APC) enhances the potency of recombinant protein CD8⁺ T cell vaccines. Recent comparisons of recombinant protein-based dendritic cell (DC) targeting vaccines revealed differences in cross-presentation and identified CD40 as a potent human DC receptor target for antigen cross-presentation. Contrary to in vitro-derived monocyte (mo)DC, we found that interferon-alpha (IFNα) stimulation of human blood-derived DC was necessary for an antigen-specific IFNγ CD8⁺ T cell response to a CD40 targeted cancer vaccine. Importantly, targeting an adjuvant in the form of IFNα to DC increased their potency to elicit antigen-specific production of IFNγ by CD8⁺ T cells. Thus, we introduce the concept of DC adjuvant targeting to enhance the potency of vaccination.



from # All Medicine by Alexandros G. Sfakianakis via alkiviadis.1961 on Inoreader http://ift.tt/2uSPUW5